Protocol Ledger

NCT04970654 · Phase III · COMPLETED

A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

Interventional Phase III clinical trial protocol NCT04970654 sponsored by Novo Nordisk in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-22 Enrollment: 110 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04970654
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)110 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04970654
Protocol FieldVerified Registry Value
NCT IdentifierNCT04970654
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment110 participants (ACTUAL)
Registered Start Date2021-07-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI